# FDA Approves Generic Version of DAPAGLIFLOZIN The U.S. Food and Drug Administration has approved Zydus Lifesciences Limited's generic formulation of dapagliflozin (ANDA211582), a widely-used SGLT2 inhibitor for diabetes and heart failure treatment, effective April 6, 2026. The approval is expected to increase competition in the oral antidiabetic market and potentially reduce drug costs for patients, as generic alternatives typically capture significant market share from branded versions.